Sat. Oct 1st, 2022

SEATTLE, July 11, 2022 /PRNewswire/ — According to Coherent Market Insights, the global recombinant DNA technology market is estimated to be valued at US$ 145.4billion in 2022 and is expected to exhibit a CAGR of 7.9% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Recombinant DNA Technology Market:

The increase in research and development activities by key players is expected to drive the market over the forecast period. For instance, in June 2021, according to data published by National Center for Biotechnology Information, Haemophilia is a rare disorder, treatments for haemophilia disorder were previously restricted to receiving blood plasma from donors who have working levels of VIII and IX clotting factors. Advancements in DNA technology have led to the production of recombinant factors VIII and IX. Hence, global data expects a lower uptake of plasma-derived haemophilia treatments in 2022 as developers focus on improving recombinant products and gene therapies.

Request Sample Copy of this Report @

Key Market Takeaways:

The global recombinant DNA technology market is expected to exhibit a CAGR of 7.9% during the forecast period due to the increasing adoption of inorganic growth strategies such as agreements by the key players in the market. In December 2021, Lupin Limited, an Indian multinational pharmaceutical company, entered into an exclusive distribution and marketing agreement with Biomm SA, a biotechnology company in Brazil. Under the terms of agreement, Biomm would distribute and market biosimilar Pegfilgrastim Lupin’ Product in Brazil. Biomm SA Company produces human and swine insulin using recombinant DNA techniques. Lupin had received the U.S. Food and DruG Administration (U.S. FDA) acceptance of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

Among application, therapeutics segment holds a dominant position in the recombinant DNA technology market, owing to rising number of genetically engineered products such as recombinant insulin, erythropoietin, and novel gene therapies to treat various human diseases. For instance, in May 2022, according to an article published by National Center for Biotechnology Information, Erythropoietin stimulating agents (ESAs) are recombinant versions of European Patent Office (EPO) produced pharmacologically via recombinant DNA technology in cell cultures. Examples of erythropoietin stimulating agents include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta.

Key players operating in the global recombinant DNA technology market include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company.

Request for Customization @ 

Detailed Segmentation:

Global Recombinant DNA Technology Market, By Product Type:

  • Recombinant Protein Drugs
    • Insulin
    • Human Growth Hormone
    • Erythropoietin
    • Interferon
    • Blood Factors
    • Colony Stimulating Factors
    • Fusion Proteins
    • Others
  • Vaccines
  • Genetically Modified Crops
  • Expression Systems
    • Prokaryotic Cells
    • Mammalian Cells
    • Yeats
    • Insect
    • Others
  • Cell and Gene Therapy
  • Gene Editing

Global Recombinant DNA Technology Market, By Application:

  • Therapeutics
  • Agriculture
  • Research

Global Recombinant DNA Technology Market, By Region:

  • North America
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By Country:
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this Complete Report Now @

Find related trending reports below:

Recombinant Vaccines Market, by Product Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), by Disease Type (Infectious Disease, Cancer, Allergy, and others), by End User (Recombinant Human Vaccines and Animal Recombinant Vaccines (Poultry, Companion Animal Vaccines, Livestock, Porcine, and Aquaculture Vaccines)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

Recombinant Human Endostatin Market, by Application (Medical Application, Scientific Application), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]  
Follow Us: LinkedIn | Twitter


SOURCE Coherent Market Insights

Source link